Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.

PubWeight™: 0.94‹?›

🔗 View Article (PMC 2150174)

Published in Br J Cancer on April 01, 1998


S R Johnston1, D O Constenla, J Moore, H Atkinson, R P A'Hern, G Dadian, P G Riches, M E Gore

Author Affiliations

1: The Melanoma Unit, Royal Marsden NHS Trust, London, UK.

Articles cited by this

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol (1992) 2.26

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet (1990) 1.80

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol (1995) 1.58

Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep (1984) 1.51

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol (1989) 1.46

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol (1994) 1.16

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol (1993) 1.16

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1996) 1.08

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol (1991) 1.07

Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res (1993) 1.04

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol (1996) 1.03

Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. Semin Oncol (1993) 0.95

Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. Br J Cancer (1990) 0.92

A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer (1993) 0.89

Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol (1991) 0.85

Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol (1993) 0.85

A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2. Semin Oncol (1993) 0.84

Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. J Clin Oncol (1991) 0.84

A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. Cancer (1990) 0.83

Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2. Tumour Biol (1993) 0.82

Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma. Melanoma Res (1993) 0.79

Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. J Natl Cancer Inst (1990) 0.78

Articles by these authors

Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol (1989) 6.86

A role for CD95 ligand in preventing graft rejection. Nature (1995) 6.07

Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA (2001) 5.52

Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol (1995) 5.43

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996) 4.99

U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol (2002) 4.92

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol (2001) 4.45

TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia (2003) 4.17

Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet (2001) 4.16

CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol (1998) 3.60

UK guidelines for the management of cutaneous melanoma. Br J Plast Surg (2002) 3.51

Psychological effects of being offered choice of surgery for breast cancer. BMJ (1994) 3.48

Research needs for the risk assessment of health and environmental effects of endocrine disruptors: a report of the U.S. EPA-sponsored workshop. Environ Health Perspect (1996) 3.34

Effectiveness of routine ultrasonography in detecting fetal structural abnormalities in a low risk population. BMJ (1991) 3.30

An analysis of the in vitro and in vivo phenotypes of mutants of herpes simplex virus type 1 lacking glycoproteins gG, gE, gI or the putative gJ. J Gen Virol (1994) 2.92

Extent of mesorectal spread and involvement of lateral resection margin as prognostic factors after surgery for rectal cancer. Lancet (1990) 2.77

Direct detection of HIV RNA expression in seropositive subjects. Lancet (1988) 2.75

Use of the polymerase chain reaction for early detection of the proviral sequences of human immunodeficiency virus in infants born to seropositive mothers. New York City Collaborative Study of Maternal HIV Transmission and Montefiore Medical Center HIV Perinatal Transmission Study Group. N Engl J Med (1989) 2.73

Infectious complications of subcutaneous interleukin-2 and interferon-alpha. Lancet (1992) 2.65

Natural history of stage IV epithelial ovarian cancer. J Clin Oncol (1999) 2.52

Molecular diagnosis of infective endocarditis--a new Duke's criterion. Scand J Infect Dis (2001) 2.36

Current status of ketamine anaesthesia. Lancet (1971) 2.28

Which gp160 vaccine? Nature (1993) 2.27

A new method for radionuclide imaging of myocardial infarcts. Radiology (1974) 2.24

Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol (2012) 2.23

Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol (2010) 2.22

Certification, accreditation, and quality control in behavior analysis. Behav Anal (2001) 2.14

Management of metastatic melanoma during pregnancy. BMJ (1998) 2.10

Lumbosacral cerebrospinal fluid volume is the primary determinant of sensory block extent and duration during spinal anesthesia. Anesthesiology (1998) 2.09

Oxybenzone oxidation following solar irradiation of skin: photoprotection versus antioxidant inactivation. J Invest Dermatol (1996) 2.07

Laryngeal mask airway for caesarean section. Anaesthesia (1990) 2.05

Human chromosome 12 is required for elevated HIV-1 expression in human-hamster hybrid cells. Science (1989) 2.03

Ovarian cancers related to minimal access surgery. Br J Obstet Gynaecol (1995) 2.02

Some historical and conceptual relations among logical positivism, operationism, and behaviorism. Behav Anal (1985) 1.99

Pumilio is essential for function but not for distribution of the Drosophila abdominal determinant Nanos. Genes Dev (1992) 1.85

Head-upright tilt-table testing in evaluation and management of the malignant vasovagal syndrome. Am J Cardiol (1992) 1.82

Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol (1999) 1.82

Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol (1996) 1.78

Stimulation of hepatic regeneration after partial hepatectomy by infusion of a cytosol extract from regenerating dog liver. Surg Gynecol Obstet (1980) 1.72

Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer (2004) 1.70

A d.c. magnetic metamaterial. Nat Mater (2008) 1.69

Head and neck sarcomas: prognostic factors and implications for treatment. Br J Cancer (1993) 1.67

Characterization of potential endocrine-related health effects at low-dose levels of exposure to PCBs. Environ Health Perspect (1999) 1.66

Evaluation of midazolam as an intravenous induction agent. Anaesthesia (1981) 1.64

Health services use by urban women with or at risk for HIV-1 infection: the HIV Epidemiology Research Study (HERS). J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.61

Postoperative radiotherapy and late mortality: evidence from the Cancer Research Campaign trial for early breast cancer. BMJ (1989) 1.59

General practitioners' and patients' models of obesity: whose problem is it? Patient Educ Couns (2001) 1.59

Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol (2005) 1.58

In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investig Dermatol Symp Proc (1999) 1.58

Characterization of the ets oncogene family member, fli-1. J Biol Chem (1993) 1.57

Subsistence strategies of two "savanna" chimpanzee populations: the stable isotope evidence. Am J Primatol (1999) 1.57

A chink in HIV's armour? Nature (1990) 1.56

Ketamine as an induction agent in anaesthetics. Lancet (1970) 1.55

Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol (2001) 1.55

Influence of cholecystectomy on symptoms. Br J Surg (1991) 1.54

Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol (1997) 1.54

Chemotherapy for symptom control in recurrent squamous cell carcinoma of the head and neck. Ann Oncol (1997) 1.53

The role of ferritin and hemosiderin in the MR appearance of cerebral hemorrhage: a histopathologic biochemical study in rats. AJNR Am J Neuroradiol (1990) 1.53

The influence of breast size on late radiation effects and association with radiotherapy dose inhomogeneity. Radiother Oncol (1994) 1.53

Colonic sulfide in pathogenesis and treatment of ulcerative colitis. Dig Dis Sci (1997) 1.52

A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Cancer (1995) 1.52

BW373U86, a delta opioid agonist, partially mediates delayed cardioprotection via a free radical mechanism that is independent of opioid receptor stimulation. J Mol Cell Cardiol (2001) 1.51

Hematopoietic lineage- and stage-restricted expression of the ETS oncogene family member PU.1. Blood (1993) 1.50

Choice and number of reinforcers. J Exp Anal Behav (1979) 1.49

Indolent cutaneous prodrome of fatal HTLV-I infection. Lancet (1990) 1.48

Non-cytocidal natural variants of human immunodeficiency virus isolated from AIDS patients with neurological disorders. Lancet (1987) 1.47

Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol (1987) 1.47

Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ (1991) 1.46

A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis (2004) 1.46

Bioinformatics construction of the human cell surfaceome. Proc Natl Acad Sci U S A (2009) 1.45

On privacy, causes, and contingencies. Behav Anal (1984) 1.42

Cesarean delivery in a patient with a transplanted heart. Anesthesiology (1989) 1.41

Women, violence, and HIV: a critical evaluation with implications for HIV services. Matern Child Health J (2000) 1.41

Effect of cold submersion on intramuscular temperature of the gastrocnemius muscle. Phys Ther (1979) 1.40

Mammographic accuracy and patient age: a study of 297 patients undergoing breast biopsy. Clin Radiol (1993) 1.40

Paramedic field instructors: an approach to training the newest paramedics while maintaining the interest of the most successful senior paramedics. Prehosp Disaster Med (1995) 1.40

Direct demonstration of the human parvovirus in erythroid progenitor cells infected in vitro. J Clin Invest (1984) 1.38

Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidone. Cancer Chemother Pharmacol (1988) 1.38

Practice parameters for the management of colonic cancer I: surgical issues. Recommendations of the Colorectal Surgical Society of Australia. Aust N Z J Surg (1999) 1.38

Tamoxifen and chemotherapy for refractory metastatic malignant melanoma. N Engl J Med (1993) 1.38

Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates. Gene Ther (2006) 1.38

A clinical evaluation of the maternal effects of lumbar extradural analgesia for labour. Anaesthesia (1974) 1.37

Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant (2005) 1.37

DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer (2006) 1.36

Why do people seek treatment by alternative medicine? Br Med J (Clin Res Ed) (1985) 1.35

North and South Amerindians may have the same major founder Y chromosome haplotype. Am J Hum Genet (1996) 1.35

Autism: recent molecular genetic advances. Hum Mol Genet (2000) 1.34

The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer (2000) 1.33

Rapid and quantitative detection of enzymatically amplified HIV-1 DNA using chemiluminescent oligonucleotide probes. AIDS Res Hum Retroviruses (1990) 1.33

Ectopic pregnancy. BMJ (2000) 1.32

Joint line restoration after revision total knee arthroplasty. Clin Orthop Relat Res (1999) 1.32

Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol (2003) 1.32

Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol (2007) 1.29

Acceptance of HIV testing during prenatal care. Perinatal Guidelines Evaluation Project. Public Health Rep (2001) 1.29

Immune-mediated thrombocytopenia of malaria. J Clin Invest (1983) 1.28

The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer (1990) 1.28